About Cygnus Technologies
Founded in 1997, and now part of Maravai LifeSciences, Cygnus Technologies specialises in analytical tools and services for bioprocess development, biopharmaceutical manufacturing and quality control. The company focuses on the detection and characterisation of process-related impurities, enabling researchers and manufacturers to assess product purity, process consistency and regulatory compliance throughout biologics development. Its expertise spans host cell protein (HCP) analysis, residual host cell DNA quantification, viral clearance assessment and impurity monitoring, supporting the development and manufacture of monoclonal antibodies, recombinant proteins, vaccines and other biologic therapeutics.
Cygnus Technologies offers a portfolio of host cell protein ELISA kits covering numerous cell culture production platforms, as well as bioprocess impurity assays for residual Protein A, Protein L and related contaminants. The company also provides host cell DNA extraction and quantification kits, viral clearance prediction assays and custom analytical services for impurity characterisation. Notable capabilities include Antibody Affinity Extraction (AAE™) combined with mass spectrometry and process-specific HCP ELISA development to support product release testing and regulatory requirements. These tools are used throughout process development, purification optimisation, clinical manufacturing and commercial quality control workflows, helping scientists evaluate impurity clearance and maintain product quality
Europa Biosite’s subsidiaries distribute for Cygnus Technologies in Austria and Switzerland.